Semaglutide is a GLP-1 receptor agonist, meaning it mimics a natural hormone in your body that helps regulate appetite and blood sugar. Originally developed to treat Type 2 diabetes, it’s now FDA-approved for weight loss under the brand name Wegovy® and commonly prescribed off-label as Ozempic®.
According to a study published in the New England Journal of Medicine, patients using Semaglutide lost an average of 14.9% of their body weight over 68 weeks—significantly more than with lifestyle changes alone.
Tirzepatide is a newer, dual-action medication that activates both GLP-1 and GIP receptors, offering an enhanced metabolic effect. Marketed under the name Mounjaro®, it was originally approved for Type 2 diabetes but is gaining attention for unprecedented weight loss results.
In the SURMOUNT-1 clinical trial, patients on Tirzepatide lost up to 20.9% of their body weight—setting a new bar for non-surgical interventions.
FeatureSemaglutideTirzepatideTypeGLP-1 onlyGLP-1 + GIP dual agonistWeight Loss Avg.~15%~20–22%FDA Approved For WLYes (Wegovy®)Pending (currently diabetes)Common BrandsOzempic®, Wegovy®Mounjaro®CostLowerSlightly higherSide EffectsNausea, constipationNausea, diarrhea (may be stronger)
That depends on your:
At SHRED Weightloss, we take time to get to know you—so your plan is built around what’s going to work for your body and lifestyle. We also offer support with nutrition, daily habits, and mindset shifts to maximize your long-term success.